HE MOST primitive hematopoietic stem cells (HSCs)
T can regenerate and maintain all the mature lymphoid and myeloid cells of the blood and marrow for the life span of the animal.'-5 Although HSCs are extremely rare, they are readily accessible, and transplantation of allogeneic or autologous bone marrow (BM) or cytokine-mobilized peripheral blood (MPB) has become an established therapy for many benign and malignant diseases including leukemias, aplastic anemias, solid tumors, and metabolic disorders. To obtain sufficient numbers of HSCs for both rapid and sustained engraftment, large numbers of unfractionated cells must be transplanted. However, unselected hematopoietic cells may contain tumor cells able to contribute to disease relapse after autologous tran~plantation.~.' To overcome this potential problem, tumor-purged, or stem cell-selected BM or MPB is increasingly being used as a source of reconstituting HSCs in this setting. CD34-selected cells contain both progenitors and HSCs capable of fully reconstituting the blood cells in 9 t o 12 days, suggesting that unseparated marrow contains early engrafting cells that were depleted by sorting. Upon ex vivo expansion, total cells, CFCs and day 12 CFU-S were amplified 2.062-, 83-and l3-fold, respectively, from TLS cells; and 1,279-, 259-and 708-fold, respectively, from TSHFU cells. Expanded cells could regenerate the majority of lymphocytes and granulocytes in primary (17 weeks) and secondary (26 weeks) hosts and were only moderately impaired compared t o fresh HSCs. The EE of TSHFU cells was more potent than that of TLS cells, suggesting that more highly enriched HSCs are more desirable starting populations for this application. When mice were transplanted with 10' TSHFU cells and their EE, the duration of thrombocytopenia was shortened from 18 t o 12 days, and anemia was abolished. Leukocytes were also elevated on days 9 t o 12, although sustained recovery was not accelerated. Anemia was also abrogated in recipients of lo' TLS cells and their EE. Early platelet counts were slightly higher than with TLS cells alone, but leukocyte recovery was not improved. These data confirm that TLS cells contribute t o early and sustained hematopoiesis, and demonstrate a benefit of ex vivo expanded cells in accelerating engraftment of more primitive TSH'" stem cells depleted of progenitors. 0 1996 by The American Society of Hematology.
lymphohematopoietic system in humans.*.' However, CD34' cells are also often contaminated with tumor cells, especially in multiple myeloma and breast Recently, analyses of the differential expression of HLA-DR, CD38, Thy-1 and other antigens have enabled further purification of CD34' cells with differing functional pr~perties.'~.'' In the case of CD34+LIN-Thy-l+ cells, this has also enabled impressive simultaneous reductions in contaminating tumor cells."
Hematopoietic reconstitution following transplantation of unfractionated MPB is characterized by a minimum 9 to 11 day period of neutropenia and thrombocytopenia when a threshold dose of granulocyte-macrophage colony-forming units (CFU-GM) or CD34' cells is administered.'*." Because of their more primitive composition, fractionated stem and/or progenitor cells may exhibit some additional delay in engraftment. Currently, transplant recipients are treated for cytopenia by the administration of recombinant granulocyte colony-stimulating factor (G-CSF) and platelet transfusions. Nevertheless, this approach does not completely abrogate the nadir in blood cell counts or usefully shorten the period of hematopoietic recovery. It has been suggested that transplantation of progenitors that have been expanded and partially differentiated ex vivozo may shorten the time to recovery of neutrophils and platelets, and reduce the number of transfusions required to support hematologic recovery. True stem cell expansion might also allow transplantation to proceed when sufficient HSCs and progenitors were not obtained during the initial collection. However, this approach is highly controversial, challenged by suggestions that progenitors have no role in early engraftment2',22 and concems that ex vivo culture may deplete HSCs with long-term repopulating potentiaLZ3
The potential clinical application of ex vivo expanded progenitor cells was demonstrated by Muench et alN who transplanted lethally irradiated mice with day 1 5-FUtreated BM (FUBM) cells that had been cultured for 1 week in interleukin-I (IL-1) and Steel factor (SLF). The expanded population was enriched 200-fold in the cells required for 30-day radioprotection, and increased leukocyte, neutrophil, erythrocyte, and platelet counts two to fivefold compared to unexpanded FUBM 4 to 10 days after transplantation. However, other investigators have failed to show a retention of long-term reconstituting stem cells when murine BM was cultured for 2 days in IL-3, IL-6, IL-11, and SLF,*' or when partially purified Thy-l'OLIN-or Sca-l+LIN-cells were expanded for 6 to 7 days in IL-3 and SLF,26 or IL-la, IL-3, IL-6, and SLF.Z7 Parallel efforts to expand human CD34+ cells have enabled significant amplification of committed progenitor^,^^^^^^^^ but only maintenance or moderate increases in more primitive long-term culture-initiating cells (LTCICS),~'.~' despite evidence from clonal analysis of LTCIC development that the latter should be p~ssible.~' Clear evidence of a clinical benefit of transplanting ex vivo expanded human hematopoietic cells is not yet apparent, suggesting that this approach requires further optimization. For example, CD34+ MPB cells expanded for 12 days in IL-10, IL-3, IL-6, SLF, and erythropoietin (Epo) can promote hematopoietic recovery in nonmyeloablated patients, but the rate of engraftment is similar to that of unseparated or CD34-selected MPB cells.33 Breast cancer patients transplanted with autologous marrow and additional BM cells that had been expanded for 12 days in PIXY321 (a recombinant fusion of human IL-3 and granulocyte macrophage-CSF [GM-CSF I) and or MPB and CD34+ MPB cells expanded for 12 days in P1XY32l3' recovered blood counts moderately faster than historical controls. Not surprisingly, CFU-GM and LTCICs were only moderately expanded under these conditions. In a separate study, hematopoietic recovery following peripheral blood (PB) cell transplantation was not accelerated by the cotransplantation of PB cells that had been expanded for 8 days in IL-10, IL-3, E-6, SLF, and Epo. Indeed, all patients required an infusion of backup cells after transplant, suggesting that culture conditions that promote excessive differentiation may not retain early or late engrafting cells.36
To date, both experimental and clinical studies of expanded hematopoietic cells have used suspensions derived from relatively heterogeneous HSCs containing large numbers of mature progenitors. Not surprisingly, such cells differentiate rapidly in vitro generating large numbers of mature cells, but decline in functional p o t e n~y .~' -~~.~~ More extensively purified, primitive HSCs are predicted to have a greater expansion potential in vitro, generating new progenitors with additional amplification potential in vivo. In this regard, the present study was designed to assess the expansion potential of highly purified long-term repopulating HSCs, and determine the value of ex vivo expanded cells as support for myeloablated mice transplanted with purified stem cells. Stem cells were isolated by two methods that coenrich more mature progenitors (eg. CFU-S) to different degrees. We show that hematopoietic recovery is accelerated in mice cotransplanted with primitive Thy-1"Sca-1 +H-2Kh1 FUBM cells (depleted of progenitors) and their expanded progeny. The expanded progeny of a more heterogeneous population of Thy-I'"LIN-Sca-l+ cells are less effective in hastening engraftment by this HSC population.
MATERIALS AND METHODS

Animals
. Four-to 6-week-old (C57BUKa.AWJ)Sys-Ptprc"-Thy-I" (known as B.Al) mice (Thy-1.1, H-2b, and Ly-5.2) were used as marrow donors. Age-matched (C57BLI6J.SJLIJ)Sys-Ptprcb-Thy-I b (known as B6.SJL) mice (Thy-1.2. H-2b, and Ly-5.1) were used as recipients. All mice were bred at the animal facility at SyStemix, Inc (Palo Alto, CA).
Femoral BM cells were collected from 10 to 12 untreated B.Al mice, or B.A1 mice that had been injected intravenously (i.v.) 24 hours previously with a sterile solution of 5-FU (Solopak Laboratories, Inc, Elk Grove Village, IL) in phosphate-buffered saline at a dose of 150 mg/kg body weight. Marrow cells were harvested into Hanks' balanced salt solution containing 2% fetal calf serum (FCS) and 0.02% sodium azide (HFN). Erythrocytes were eliminated by hypotonic lysis, and the leukocytes magnetically-depleted of mature lymphoid and myeloid cells as previously de~cribed.~' When FUBM was used as the starting material, lineage-depleted cells (4% of the original suspension) were processed as previously described to isolate a population of Thy-1'"Sca-1'H-2Kh' (TSHFU) cells." When normal mmow was used as the starting material, lineage-depleted cells (7% of the original suspension) were labeled with phycoerythrin (PE)-conjugated goat antirat IgG antibody (Southern Biotechnology Associates, Inc, Birmingham, AL) to identify lineage+ cells remaining after bead depletion. After washing, cells were incubated with saturating amounts of unconjugated anti-CD32 (F,Rg, clone 2.462), fluorescein isothiocyanate (FITC)-conjugated anti-Thy-1.1 (clone 19XE5) and biotinylated anti-Ly-6AE (Sca-1; clone E13-161.7) monoclonal antibodies (MoAbs) (all except 19XE5 from Pharrningen, San Diego, CA), then washed again and stained with Texas Red (TX)-labeled streptavidin (Biomeda Inc, Foster City, CA), and finally washed and resuspended in HFN containing 5 pg/mL propidium iodide (PI). Lineage-depleted cells left unstained, or stained with IgG,-FITC, IgC,.-PE and Ig-G,,-biotin isotype MoAbs (Phanningen, San Diego, CA) and streptavidin-TX were used as background controls. Cell sorting was performed on a dual-laser FACStar-Plus instrument (Becton Dickinson Immunocytometry Systems, San Jose, CA). TSH" 37 or Thy-1'"LIN-Sca-1' (TLS)38 cells were isolated from PI-cells (see Fig 1) . Reanalysis of these populations immediately after sorting indicated a reproducible purity of 290%.
One thousand TSHN or TLS cells were cultured in 1.0 mL RPMI 1640 medium containing 5% FCS (Stemcell Technologies Inc, Vancouver, Canada), 50 UI mL penicillin G, 50 pg/mL streptomycin, 2 mmol/L L-glutamine and 0.05 mmoVL 2-ME. Recombinant IL-3, IL-6, GM-CSF (R & D Systems, Minneapolis, MN) and/or G-CSF (Amgen Inc, Thousand Oaks, CA) were added at 10 ng/mL. SLF (R & D Systems) was added at 100 ng/mL. Cultures were incubated at 3 7 T and all cells procured after 7 days.
Unseparated or sorted BM cells (100 to 3 X lo4 per dish) were plated in 35" petri dishes was generated by the maximum-likelihood method, and the frequency of CRU then calculated using standard statistical methods by interpolation of the number of test cells required to obtain a 37% negative response?"'." Ly-5. I mice were irradiated as above and injected with 10' sorted (Ly-5.2') BM cells, the expanded progeny of IO' sorted BM cells generated after 7 days of culture in IL-3. IL-6, G-CSF, and SLF, or the two populations together. Mice were bled from the retro-orbital sinus on days 3, 6, 9, 12, 15, 18, 25, 32, 47, 56, and 119 after transplantation. Until day 25, only half of the mice in each cohort were analyzed alternately at each time so that no individual animal was bled more frequently than every 7 days. Circulating leukocyte, erythrocyte and platelet counts were determined by analysis of 40 pL of blood using a System 9000 Hematology Series Cell Counter (Serono Diagnostics Inc, Allentown, PA). On day 119, donor-derived PB lymphocytes and granulocytes were quantitated by flow cytometry as described above. Marrow cells were assayed for CFCs, and injected into lethally irradiated Ly-5. I mice (0.5 femurslmouse) for secondary repopulation. Secondary mice were analyzed 26 weeks later for donorderived PB leukocytes.
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RES U LTS
Enrichment .f hemntopoietic stem cells from normnl and 5-FU-tre~ted BM. Two methods were used to isolate hematopoietic stem cell populations that differed in their content of more mature progenitor cells (Fig I) . Firstly, primitive cells were enriched from normal BM by gating of blasts exhibiting low side and intermediate-high forward light-scattering properties (Fig I B) . Lymphoblasts exhibiting low lev- FACS selection of Thy-I'"LIN~Sca-l+ (TLS) and Thy-1"Sca-l+H-2Kh' (TSHF") cells is shown in Fig 1. Shown are the mean 2 SEM values from (n) different experiments. Spleen colony numbers are not corrected for seeding efficiency, and represent actual counts. CFC numbers represent total CFU-G/M/GM, erythroid burst-forming units (BFU-E), and mixed colony-forming cells (CFU-GEMM).
levels of H-2Kb antigen (Fig 1E) represented 0.026 ? 0.003 % (n = 11) of FUBM (ie, 1 per 3,846 cells).
Quantitation of progenitor cells in Thy-l"LIN-Sca-lc BM and Thy-l'*Sca-l+H-2Kh' FUBM. To determine the frequency of mature clonogenic cells in the sorted populations, we performed assays for CFCs and CFU-S ( Table I) . CFCs were present at a frequency of 2.7 per lo3 normal marrow cells, and were reduced -10-fold after exposure to 5-FU in vivo (Table 1 ). CFCs were highly enriched from both NBM and FUBM after sorting, representing 435 per 10' TLS cells (160-fold), and 171 per lo3 TSH"' cells (552-fold). Primitive BFU-E, CFU-GM and CFU-GEMM were all present among TLS cells at approximately equivalent proportions to that present in unseparated marrow (data not shown). Strikingly, -80% of the colonies generated by TSHN cells were mixed. This is consistent with the increased sensitivity of the more mature classes of CFCs to 5-FU,47 and their exclusion from the TSH"' population because of their lower level of H-2K antigen expre~sion.~~ Day 8 and day 12 CFU-S each represented 0.17 per lo3 normal BM cells (Table 1) . Following exposure to 5-FU, day 8 CFU-S were reduced to undetectable levels, and day 12 CFU-S were reduced 8.5-fold to 0.02 per lo3 cells. Day 8 and day 12 CFU-S were enriched to a frequency of 17 (100-fold) and 74 (435-fold) per 10' TLS cells, respectively ( Table I) . Day 12 CFU-S were also enriched 75-fold in the TSHW population, but their final frequency of 1.5 per lo3 cells remained -49-fold lower than in the TLS fraction isolated from normal marrow. Therefore, compared to TLS cells, TSHm cells contain fewer progenitors with rapid and short-term proliferative potential.
Quantitation of competitive long-term repopulating stem cells. To assess the long-term reconstitution potential of the two enriched stem cell populations, we used a quantitative competitive repopulation assay.40 Limiting numbers of sorted cells (0 to 250 per mouse) were injected into lethally irradiated Ly-5 congenic recipients together with lo5 twice serially transplanted Ly-5 congenic BM cells to provide radioprotection. Ten weeks after transplantation, the proportion of mice exhibiting 2 5 % donor-derived (Ly-5.2') cells among B and T lymphoid, and granulocytic compartments were used to calculate the frequency of CRU in the original sorted population. We used 10 weeks as an end-point for this analysis because it was previously shown that the results are not significantly different when recipients are assessed between 10 weeks and 1 year after tran~plant.~~ We recently reported that CRU represent 1 per 55 (95% confidence limits 1 per 43 to 1 per 74) TSHFU cells.37 This data is shown again in Table 2 for comparison to the results of three experiments performed with TLS cells. CRU represented 1 per 43 (95% confidence limits 1 per 31 to 1 per 69) TLS cells. This is not statistically different from the CRU frequency in the TSHN subpopulation. Therefore, although TSHN cells are totally depleted of day 8 CFU-S and contain -50-fold fewer day 12 CFU-S, they contain a similar frequency of more primitive stem cells with competitive long-term repopulating potential.
Ex vivo expansion of Thy-l'"LIN-Sca-l+ BM and Thy-I'"Sca-l+H-2Kh' FUBM. To compare the proliferative potential of the two stem cell populations in vitro, lo3 sorted cells were cultured in various combinations of recombinant cytokines and the total number of nucleated cells counted after 7 days (Fig 2) . Neither population proliferated in cultures containing IL-3, IL-6, G-CSF, GM-CSF or SLF alone. However, consistent with previous studies of the effect of SLF on highly enriched HSCS?'-~' cultures containing SLF alone did contain some viable cells after one week. TLS cells proliferated extensively in cultures containing SLF and either IL-3 (1,213 t 75-fold), IL-6 (691 5 164-fold), G-CSF (1,005 ? 256-fold) or GM-CSF (688 t 88-fold). However, the greatest expansion was observed in cultures containing 3 or 4 factors including SLF; for example, 2,062 ? 220-fold in IL-3+IL-6+G-CSF+SLF and 1,557 ? 204-fold in IL-3 +ILd+GM-CSF+SLF. Exclusion of IL-6 or G-CSF, but not GM-CSF, from these combinations resulted in a 13% to 22% decline in nucleated cell production. TSHFU cells required at least 3 cytokines for significant growth. The greatest expansion was obtained in IL-3+IL-6+G-CSF+SLF (1,279 ? 151-fold), but was still 38% less than that of TLS cells after 1 week (Fig 2) . This difference presumably reflects the more primitive composition of TSHFU cells, which likely require an extended culture period for maximal expansion.
Expansion of progenitors in cultures of Thy-1'"LlN-Sca-I + BMand Thy-I'"Sca-l+H-2Kh' FUBM. To investigate the functional activity of the cells generated after stem cell expansion, we performed assays for CFCs and CFU-S. (Fig 3) . In comparison, CFCs in the TLS population were expanded only 11 t 2-fold in SLF+IL-3, 35 ? 13-fold in SLF+IL-6, 20 ? 2-fold in SLF+G-CSF and 4 f 1-fold in SLF+GM-CSF. Like total cell production, expansion of CFCs was highest in cultures containing 3 or 4 cytokines. Each purified population generated equivalent numbers of progenitors when cultured in IL-3+G-CSF+SLF, IL-3 +IL-6+SLF, or IL-3+IL-6+GM-CSF+SLF; -25,000 per culture from TSHFU cells, and -20,000 per culture from
For (Fig  3) . The expanded progeny of TSHN cells always contained a higher proportion of CFCs (up to -15%) than the progeny of TLS cells ( 5 2 % CFCs). This was particularly pronounced in cultures in which cell division was minimized by excluding IL-3 (Table 3 ). Under conditions of maximal cell production (IL-3+IL-6+G-CSF+SLF), progenitors comprised 2% to 3% of expanded cells (Table 3) .
CFU-S were quantitated only among the cells generated in IL-3+1L-6+G-CSF+SLF. Day 8 and day 12 CFU-S were amplified 44-and 13-fold in cultures initiated with TLS cells, and >476 and 708-fold in cultures initiated with TSH"' cells, respectively. Consistent with the high number of CFCs and CFU-S detected in the expanded progeny of TSHFU cells, >90% of the cells exhibited a blastoid morphology (data not shown). In addition to blasts, expanded TLS cells also contained -30% maturing myeloid cells including granulocyte precursors and monocytes.
Engraftment kinetics of Thy-I'"LIN-Sca-l+ BM and Thy-1"Sca-I'H-2K'" FUBM. Although the two enriched stem cell populations contain a similar frequency of CRU, they differ by -3-to 49-fold in their content of CFCs and CFU-S. To determine whether this difference in the number of progenitor cells might influence the time to recovery of circulating blood cells, 1 O3 sorted cells were injected into lethally irradiated Ly-5 congenic mice and blood counts monitored for 4 months. The levels of leukocytes (7.9 to 11.5 X IO3/ pL), erythrocytes (8.5 to 10.3 X 10h/pL) and platelets (7.7 to 10.6 X 10s/pL) in normal mice are shown by the shaded areas in the upper portion of each graph in Fig 4. The decline in circulating blood cells after irradiation is shown by the thick lines in each panel. Nineteen of 22 (86%), and 13 of 20 (65%) recipients of lo-' TSH" or TLS cells, respectively, survived for the entire period of analysis (4 experiments each) and exhibited biphasic leukocyte recovery (Fig 4A and  B) . Consistent with the more primitive composition of TSH"' cells, the peak of the first engraftment phase was slightly delayed (day 18) but (-2X) larger than that observed with TLS cells (day 15). In mice injected with TSH" cells, leukocytes fell transiently on day 25, but remained above 2,OOO/pL at all times after day 15 and recovered to pretransplant levels by day 47. In recipients of TLS cells, leukocytes recovered to >2,OOO/pL by day 12 but fell to a nadir of Mice injected with IO' TSHFu cells also exhibited a decline in erythrocytes which reached a nadir of -30% of normal on day 15 (Fig 4C) . Thereafter, red cells increased rapidly, recovering to SO% of normal on day I8 and reaching normal levels after day 25. Erythrocytes never fell below 50% of normal in recipients of 10' TLS cells, and also recovered to normal levels by day 25 (Fig 4D) . Platelets recovered to 200,000/pL 18 and 15 days after transplantation of IO' TSHFU or TLS cells, respectively, but remained slightly below normal 4 months later in both groups (Fig 4E and F) .
These engraftment kinetics of 10.' enriched stem cells were compared to that of unseparated normal or 5-FU-treated marrow cells also containing IO' TLS or TSH" cells, respectively. Thirteen mice injected with 2.78 X 10' normal marrow cells recovered 2,000 leukocytes/pL and 200,000 platelets/pL in 9 and 12 days, respectively, and exhibited only an -10% decline in erythrocytes (Fig 4B, 4D, and 4F ). Leukocyte and platelet recovery was slightly slower in 13 (Fig 4C) . Therefore, the rate of hematologic recovery in myeloablated recipients of 10' purified cells was significantly slower than that in mice injected with whole BM containing an equivalent number of phenotypically-defined stem cells.
To understand these findings, we calculated the absolute number of progenitors in these cell suspensions from the data in Table I . Table 4 shows that mice injected with unfractionated normal marrow received 7,534 2 500 CFCs, 473 2 56 day 8 CFU-S, and 473 2 28 day 12 CFU-S, representing a 17-, 28-and 6-fold increase, respectively, over the number of such progenitors present in 10' TLS cells. Mice injected with unfractionated FUBM cells received 7-and SI-fold more CFCs and day 12 CFU-S than that present in 1 0' TSH' cells (Table 4) . Because all of the CRU activity in normal and 5-FU-treated marrow from B.AI mice is present in the Thy'"L1N-Sca-1 + and Thy-1 '"Sca-1 +H-2Kh' subfractions, respectively4' (S.J. Szilvassy, unpublished observations, December 1995), and both of these populations contain a similar number of CRU (Table 2 ), these findings suggest that the regeneration of circulating blood cells early after transplantation may depend on the infusion of hematopoietic cells other than CRU such as CFCs, CFU-S, and/or terminally differentiated cells.
Cotransplantation of ex vivo expanded cells promotes more rapid hematologic recovery in recipients of Thy-I"'Sca-I + H-2K"' cells depleted of progenitor activity. To determine if the rate of hematopoietic reconstitution by enriched stem cells could be accelerated by cotransplanting large numbers of progenitors and/or mature cells, lethally irradiated mice were injected with the expanded progeny of IO' sorted cells generated after 7 days of culture in IL-3, IL-6, G-CSF and SLF. In contrast to the 14% mortality observed in recipients of 10' fresh TSHru cells, all I 1 mice injected with their expanded progeny survived For personal use only. on October 23, 2017. by guest www.bloodjournal.org From for the entire 4-month period of analysis. Leukocytes recovered to >2,OOO/pL in 9 days, but then decreased to a nadir of -I,OOO/pL on day IS (Fig SA) . Sustained leukocyte recovery was apparent on day 18, and reached normal levels after day 47. Erythrocytes decreased only 9% below normal on day 9 after transplant ( Fig SC) . Importantly, platelet recovery was more rapid with expanded than freshly isolated TSH'" cells (-I4 v 18 days to 200,000/ pL), but remained -30% below normal after 119 days (Fig SE) . Further shortening of thrombocytopenia was achieved in 13 mice (0% mortality) cotransplanted with 10' TSH'" cells together with their expanded progeny. These animals recovered 200,000 platelets/pL by 12 days after transplantation, and reached near normal levels by day 56 (Fig SE) . The total duration of thrombocytopenia was thus reduced from -9 to 4 days by cotransplantation of ex vivo expanded cells. Anemia was also prevented in mice injected with sorted and expanded TSH"" cells ( Fig  5B) . Surprisingly, the early burst in leukocyte counts observed 18 days after injection of sorted cells alone was markedly diminished by the cotransplantation of their expanded progeny (Fig SA) . Thus we observed a dominant negative effect on the leukocyte recovery profile of the cultured cells over that of freshly isolated stem cells. Although sustained recovery was not hastened, leukocytes were >2,OOO/pL 9 to 12 days after transplant, and the total duration of leukopenia (ie, <20% normal counts)
was shortened from IS to 1 I days.
All 12 mice injected with the expanded product of IO' TLS cells also survived 4 months, representing a complete prevention of the 35% mortality observed with noncultured stem cells. Leukocytes and platelets recovered to safe levels in 25 and 18 days, respectively (Fig 5B and F) , and erythrocytes declined by only 20% (Fig SD) . Eleven mice were cotransplanted with IO' TLS cells together with their expanded progeny. All survived 4 months, but did not exhibit more rapid leukocyte recovery than mice injected with freshly sorted TLS cells alone (Fig SB) . As noted above in experiments with sorted and expanded TSH'" cells, the early leukocyte engraftment phase observed with TLS cells alone was unexpectedly abrogated by the cotransplantation of their expanded progeny, possibly suggesting a feedback inhibition of early sterdprogenitor cell recruitment by large numbers of differentiated cells. The time to recover 200,000 platelets/ pL (1 5 days) also was not shortened in mice injected with IO'TLS cells with or without expanded cells, although platelet counts were -twofold higher on day 12 in recipients of sorted and expanded cells (Fig SF) . Finally, the expanded progeny of TLS cells prevented the moderate anemia observed with TLS cells alone (Fig SD) . A summary of the clonogenic cell content and engraftment kinetics of sorted and/or expanded stem cells is shown in Table 4 .
Secondan! RM transplantation with enriched stem cells and/or their ex vivo expanded progeny On day 1 19 after transplant, mice were sacrificed and the proportion of blood cells derived from the sorted and/or expanded cells quantitated by staining with a donor (Ly-5.2)-specific antibody. All mice injected with either enriched HSC population contained -94% donor-derived leukocytes, which contributed the majority of circulating B and T lymphocytes and granulocytes (Table 5) . Importantly, mice transplanted with expanded cells alone also contained predominantly donor-derived leukocytes, albeit at slightly lower levels than that in mice injected with uncultured stem cells; 82 ? 7% and 75 2 7% in recipients of expanded TSH'" or TLS cells, respectively ( Table 5 ). Mice cotransplanted with sorted and expanded HSCs also contained -94% donor cells detected in both lymphoid and myeloid compartments. Marrow cellularity was normal in all mice injected with sorted and/or * Mean t SEM number of CFCs (total BFU-E, CFU-G/M/GM, and CFU-GEMM) and CFU-S.
t Spleen colony counts not corrected for seeding efficiency.
+ Unseparated BM cells contain lo3 of the phenotypically-defined candidate HSCs indicated.
5 Zero days to recovery signifies no decline below 50% normal red blood cell count.
expanded Thy-1'"Sca-1 +H-2Khi cells, and in recipients of TLS cells with or without their expanded progeny ( Table 6 ).
Recipients of expanded TLS cells alone exhibited a 25% reduction in marrow recovery. CFCs recovered to 63% to 74% of normal in all mice injected with sorted and/or expanded TSHFU cells, but were 40% to 60% below normal in recipients of sorted and/or expanded TLS cells (Table 6 ).
Retransplantation experiments revealed that all mice also recovered stem cells able to regenerate and maintain hematopoiesis in secondary hosts, 43 weeks after they were originally isolated. Secondary engraftment with expanded cells alone was moderately lower than that of sorted cells (with or without their expanded progeny), but still usually comprised the majority of lymphocytes and granulocytes (Table  5) . Therefore, although the present experiments do not allow quantitation of HSCs in the expanded suspensions, these data indicate that repopulating stem cells able to regenerate and maintain lymphomyelopoiesis were not completely exhausted during ex vivo expansion.
DISCUSSION
In this study we compared the expansion potential and engraftment kinetics of two highly enriched stem cell populations containing a similar number of competitive long-term repopulating units, but which differ by -50-fold in their content of day 12 CFU-S. Thy-li0Sca-1+H-2Khi cells from 5-FU-treated marrow contain only -17% in vitro CFCs, and are essentially devoid of day 8 and day 12 CFU-S. However, as few as 25 sorted cells could regenerate and maintain lymphocytes and granulocytes in 50% of myeloablated mice, despite the requirement to compete with a compromised but radioprotective graft of lo5 serially transplanted BM cells. Limiting dilution analysis established that CRU represented 1 per 55 TSH"' cells.37 Lethally irradiated mice transplanted with 10' TSHFU cells (containing 14 to 23 CRU) recovered safe levels of circulating leukocytes in 15 days, and erythrocytes and platelets in 18 days. Blood cells recovered to pretransplant levels in -1 month, and >80% of the lymphocytes and granulocytes were of donor origin after 4 months. Marrow progenitors also recovered to 74% of normal numbers, and included stem cells able to sustain lymphomyelopoiesis in secondary mice 43 weeks after their initial isolation.
These results were compared to that obtained with Thy-1'"LIN-Sca-1 + cells isolated from normal marrow3* that are highly enriched in in vitro CFCs (-44%) and day 12 CFU-S (74% assuming a seeding efficiency of 10%).38,5' Although the long-term repopulating ability of this population is well establi~hed,2',~~ stem cells have not previously been measured using an assay which uses limitingdilution analysis and donor-derived repopulation instead of recipient survival as an end-point for stem cell quantitat i~n .~' CRU represented 1 per 43 TLS cells, which is not significantly different from their frequency among TSHFU cells. Lethally irradiated mice transplanted with lo' TLS cells (containing 15 to 32 CRU) recovered 20% normal levels of circulating leukocytes and platelets more rapidly (12 to 15 days) than recipients of lo' TSHFU cells, and erythrocytes never fell below 50% of normal. More than 60% of lymphocytes and granulocytes were derived from TLS cells 4 months after transplant. Marrow progenitors recovered to only 41% of normal numbers after 4 months, but also included HSCs able to repopulate secondary hosts.
Irradiated mice transplanted with 3.85 X lo6 unfractionated FUBM cells (containing lo3 TSHFU cells, as well as 1, 194 CFCs and 77 day 12 CFU-S) recovered 20% normal levels of leukocytes and platelets 3 and 5 days faster than mice injected with lo3 sorted TSHFU (containing 171 CFCs, no day 8 CFU-S and 1 to 2 day 12 CFU-S). A similar improvement in recovery kinetics over 10' TLS cells was observed in mice injected with 2.78 X lo6 unfractionated normal BM cells (containing lo3 TLS cells, as well as 7,534 CFCs, 473 day 8 and 473 day 12 CFU-S). These data suggest that the delayed engraftment of purified stem cells may be related to the depletion of progenitors and/or mature cells after selection, and are in agreement with previous data suggesting that the most primitive stem cells are not primarily responsible for initial reconstitution after transplantation. For example, serially transplanted bone marrow cells, which contain reduced numbers of long-term repopulating stem cells but normal numbers of CFU-S and CFU-GM;' promote normal initial hematopoietic recovery but exhibit impaired function 3 weeks after transplantation.s3 Recently, more sophisticated separation using counterflow centrifugal elutriatiod' or Rhodamine-123 staining".''.'' has enabled prospective identification and isolation of clonogenic cells that are active at different times after transplantation. Our observation that enriched stem cells exhibit biphasic reconstitution of leukocytes lends additional support to these studies. Interestingly, repopulation experiments with allophenic murine marrow demonstrate that genotypic differences can account for the differential contribution of functionally distinct stem cell populations to the early and late phases of engraftment."' Taken together, these data imply that clinical strategies directed at curing diseases of the immunohematopoietic system by transplantation of small numbers of fractionated stem cells may have to anticipate some delay in initial hematologic recovery.
One approach toward accelerating hematopoietic recovery following myeloablation is to infuse large numbers of maturing blood cells generated by partial differentiation of stem cells in vitro. In a direct comparison of the efficacy of 14 different combinations of hematopoietic growth factors to expand TLS or TSH'I" stem cells, it was observed that IL-3+1L-6+G-CSF+SLF yielded the greatest amplification of nucleated cells and colony-forming cells. Interestingly, although TLS cells generated more cells after 7 days (>2,000-fold), TSH" cells generated more CFCs (259-fold). However, because we measured the output only at day 7, and these two stem cell populations are likely to generate maximal numbers of cells at different days of culture, these data do not allow a direct comparison of their ultimate proliferation potential. As expected, maximal expansion of either stem cell population required 3 or 4 cytokines, but was accompanied by a decline in progenitor concentration. When mice were transplanted with the expanded progeny of 109
TSHm cells (containing 44,314 CFCs, 476 day 8, and 1,062 day 12 CFU-S), the anemia observed with IO' uncultured TSHFu cells was completely abrogated, leukocyte recovery was shortened from 15 to 9 days and platelet recovery from 18 to 14 days. Leukocytes fell slightly on day 15, but the interval and degree of long-term recovery was only moderately impaired compared to uncultured stem cells. Marrow progenitors recovered to 67% of normal levels, and the regeneration of lymphocytes and granulocytes was only moderately lower than in primary and secondary recipients of freshly sorted TSHFU cells. Mice injected with expanded TLS cells (containing 35,978 CFCs, 742 day 8 CFU-S, and 970 day 12 CFU-S) also had no posttransplant anemia, but did not exhibit significant acceleration of leukocyte or platelet recovery. Furthermore, ex vivo expansion resulted in some impairment of late hematopoiesis, as exhibited by the subnormal recovery of leukocytes (Fig 5B) and progenitors ( progeny generated after culture for 7 days in IL-3, IL-6, G-CSF, and SLF. Primary mice were analyzed 17 weeks after transplantation. Secondary recipients were injected with 0.5 femurs/mouse and analyzed 26 weeks later.
both expanded suspensions contained similar numbers of progenitors (Table 4) . It is important to note, however, that the quantitative data in Table 4 does not convey the clear differences noted in the size and lineage composition of the colonies generated by each stem cell population before and after expansion. Colonies generated by Thy-l'"LIN-Sca-l+ cells in particular were much smaller and more restricted than those generated by 5-FU -resistant Thy-1'"Sca-1+H-2Kh' cells, especially after expansion. Therefore, despite their large numbers, some progenitors generated in culture may be qualitatively inferior to those in fresh marrow. One of the most striking results of this study was the unexpected finding that the first leukocyte recovery phase observed with sorted stem cells alone was inhibited by cotransplantation of their ex vivo expanded progeny. This observation raises the intriguing possibility that negative feedback signals from terminally differentiated cells and/or progenitors may regulate the recruitment of more primitive stem cells in vivo. The present experiments do not address whether this phenomenon is unique to cells that have been manipulated in culture, but have obvious implications for their clinical application. Although the mechanism for this is unclear, it is possible that the expansion conditions used (7 days in IL-3+IL-6+G-CSF+SLF) favor the production of myeloid precursors that differentiate into macrophages secreting high levels of stem cell inhibitors such as macrophage inflammatory protein-la (MIP-la). MIP-la prevents the recruitment of progenitors, but not long-term repopulating stem cells in V~V O~ ' ,~~ and this might explain the diminution of early leukocyte engraftment in mice cotransplanted with sorted and expanded cells. Further optimization of this system may therefore be achieved through the manipulation of culture conditions that reduce the de novo production of cytokines which diminish the potency of expanded cells.
The present experiments show the ability of partially differentiated ex vivo expanded cells derived from highly purified stem cells to accelerate hematopoietic recovery after stem cell transplantation. Importantly, the degree to which expanded cells may promote early reconstitution appears dependant on the maturity of the stem cells from which they are generated, and the culture conditions, both of which will influence the composition and potency of the final product. We believe that the relatively disappointing clinical experience to date with ex vivo expanded human stem cells is a For personal use only. on October 23, 2017. by guest www.bloodjournal.org From reflection of these variables and further optimization of human stem cell expansion is warranted. This approach may be particularly useful with very primitive stem cells that have been rigorously purified to remove contaminating tumor cells, but which may as a result exhibit some delay in recovery kinetic^.^' In the future, ex vivo expansion may also improve gene transfer to primitive stem cells and facilitate simultaneous tumor cell purging, allowing the generation of cellular therapeutics which will find application in a variety of clinical indications.
